In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alder nets $277.7mm through convertible debt sale

Executive Summary

Alder BioPharmaceuticals Inc. (antibody therapeutics) netted $277.7mm (including the over-allotment) through the underwritten public offering of $287.5 million aggregate principal amount (upsized from $200mm) of 2.50% convertible senior notes due 2025. The notes convert to common at a rate of 49.3827 shares per 1k principal, or $20.25 per share. Earlier this month, as part of a patent litigation settlement, Alder gained non-exclusive worldwide rights (excluding Japan and Korea) to Teva's CGRP (calcitonin gene-related peptide) antagonist antibodies patent portfolio, which includes rights to the Phase III migraine compound eptinezumab. The company plans to put the proceeds toward development, regulatory, and commercialization activities related to eptinezumab. As a result of this financing, Alder's recent $250mm preferred stock purchase agreement with Redmile Group was terminated.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO

Related Companies